Bayer is navigating one of the most complex moments in its recent history. The stock has risen nearly 5% over the past week to €38.26, and on a 12-month view it has gained almost 45%. Yet since the start of the year the advance is a paltry 0.62%, underscoring how quickly the narrative has shifted from recovery to a bundle of unresolved risks.
The tension is easy to see in the chart. At €38.26, the shares sit just above the 50-day moving average of €37.76 but remain well below the 100-day line at €39.64, which now acts as immediate resistance. The relative strength index reads a neutral 58, while 30-day annualised volatility of roughly 32% tells investors that the market is deeply uncertain about the direction of travel. The stock still trades 23% below its 52-week peak of €49.93.
Pipeline bets that could shift the story
Behind the share price stagnation lies a string of operational moves that deserve more attention than they have received.
On 17 June, Bayer closed the acquisition of Perfuse Therapeutics, a biotech focused on eye diseases. The deal comes with an upfront payment of $300 million and the potential for milestone payments that could take the total consideration to $2.45 billion. The prize is PER-001, an endothelin receptor antagonist in Phase II development for glaucoma and diabetic retinopathy. With that, Bayer gains full control of a promising ophthalmology asset.
At the same time, the European Medicines Agency is reviewing a marketing authorisation application for Asundexian, a Factor XIa inhibitor designed to prevent ischaemic stroke in adults. Bayer says it is the first such application for a Factor XIa inhibitor in Europe. The company has also filed for approval in the United States and China, and both regulators have granted priority review. Asundexian’s strategic importance is hard to overstate. Xarelto, Bayer’s blockbuster anticoagulant, is losing patent protection, and Asundexian is the designated successor meant to fill the revenue gap.
Washington turns up the heat
While the pipeline advances, political headwinds are gathering force on the other side of the Atlantic. The US Trade Representative, Jamieson Greer, has launched a formal investigation into German drug pricing under the Trade Act. The core complaint is that artificially low German drug prices force American patients to shoulder a disproportionate share of global pharmaceutical R&D costs. The trigger was reform plans from Berlin’s health ministry, which wants to close a multibillion-euro hole in the statutory health insurance system by demanding lower drug prices, including new rebates and mandatory discounts from 2027.
Should investors sell immediately? Or is it worth buying Bayer?
If the investigation leads to tariffs on German pharmaceuticals, the consequences for Bayer would be direct. Europe’s largest drug production base for the US market would face a sharp recalibration of its North American margins. A public hearing on the possible tariffs is scheduled for 22 September. Until then, the trade threat remains a concrete overhang on the stock.
Big shareholders trim their exposure
The rising political risk has prompted at least two large investors to reduce their holdings. The government of Singapore cut its voting rights stake from above 4% to 2.90%. Goldman Sachs likewise sold down its position, now holding 4.84%. Both moves add to the sense that some institutional money is wary of the accumulating liabilities.
Financially, the burden is considerable. Chief Financial Officer Wolfgang Nickl expects cash outflows of roughly €5 billion in 2026 from litigation alone, which would push free cash flow into negative territory of between €1.5 billion and €2.5 billion. Net debt stood at €32.5 billion at the end of March. A growing chorus of shareholders is pressing for a strategic review of the corporate structure, with a possible spin-off of the Consumer Health division seen as a way to unlock value that the market currently prices at a discount.
A calendar full of inflection points
The coming months are packed with events that could tip the balance. On 9 July, a final hearing on Bayer’s multibillion-dollar settlement of glyphosate claims is due in St. Louis. That will be followed by the trade hearing in September. Meanwhile, the EMA’s decision on Asundexian, expected later this year, will show whether the pipeline can deliver a genuine successor to Xarelto.
Bayer’s medium-term targets are ambitious: mid-single-digit pharmaceutical growth from 2027 and an operating margin of roughly 30% by 2030. The Perfuse acquisition and the Asundexian application give those goals concrete regulatory and clinical milestones. But the stock is unlikely to break out of its sideways pattern until the legal picture clears and the pharmaceutical pipeline moves from promise to delivery. Asundexian, in particular, is the test that could fundamentally alter how the market values the company.
Ad
Bayer Stock: Buy or Sell?! New Bayer Analysis from June 22 delivers the answer:
The latest Bayer figures speak for themselves: Urgent action needed for Bayer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from June 22.
Bayer: Buy or sell? Read more here...
